Yorvipath (palopegteriparatide), a treatment for hypoparathyroidism previously known as TransCon PTH, now is available to patients in Germany and…
Articles by Marisa Wexler, MS
The European Commission has approved palopegteriparatide, also known as TransCon PTH, to treat adults with chronic hypoparathyroidism.
The experimental therapy TransCon PTH was effective at controlling hypoparathyroidism caused by neck surgery for most patients in…
Hypoparathyroidism may play a role in serious health complications that require hospitalization for people with the disorder, but is…
Using an imaging technique called near-infrared autofluorescence (NIRAF) during thyroid surgery can help to lower the risk of hypoparathyroidism…
Online enrollment of an expanded access program for TransCon PTH, an experimental hormone replacement therapy for hypoparathyroidism, is…
Most experts report similar practices for how they monitor blood and urine tests in people with chronic hypoparathyroidism, but…
Treatment with AZP-3601, Amolyt Pharma’s experimental therapy for hypoparathyroidism, safely brought calcium levels to within normal ranges in…
Ascendis Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its treatment candidate…
Adults with hypoparathyroidism given long-term treatment with Natpara are less likely to experience heart-related health problems, according to an analysis of data…